The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation ...

A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

A class of antivirals called Pin1 inhibitors could reduce or stop outbreaks of herpes simplex virus 1 (HSV-1), the common ...

Disclaimer: This article is for informational purposes only and does not provide medical advice. Always consult a qualified ...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of ...

Explore how Pin1 inhibitors function as antivirals for herpes simplex virus, presenting a new avenue for HSV-1 therapy.

Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV ...

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...

After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major ...

Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected ...